FDA premarket approval submissions are more often backed by patents produced by physician-owned startups than patents from nonphysician-owned startups, a Wolters Kluwer Health study finds. Researchers warn that enforcing burdensome financial disclosure rules could deter medtech firms from investing in physician-owned startups, which could hurt innovation.
Tough transparency rules could harm innovation, researchers warn
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan